| Literature DB >> 23551890 |
Maria H Nilsson1, Mitesh Patel, Stig Rehncrona, Måns Magnusson, Per-Anders Fransson.
Abstract
BACKGROUND: Deep brain stimulation (DBS) in the subthalamic nucleus (STN) significantly reduces symptoms of Parkinson's disease (PD) such as bradykinesia, tremor and rigidity. It also reduces the need for anti-PD medication, and thereby potential side-effects of L-Dopa. Although DBS in the STN is a highly effective therapeutic intervention in PD, its mechanism and effects on oculomotor eye movement control and particularly smooth pursuit eye movements have to date rarely been investigated. Furthermore, previous reports provide conflicting information. The aim was to investigate how DBS in STN affected oculomotor performance in persons with PD using novel analysis techniques.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23551890 PMCID: PMC3621588 DOI: 10.1186/1743-0003-10-33
Source DB: PubMed Journal: J Neuroeng Rehabil ISSN: 1743-0003 Impact factor: 4.262
Patients’ characteristics and scores of the UPDRS part III
| Age (years) at surgery, mean (SD) | 63.2 (3.9) |
| PD-duration (years), mean (SD) | 16.3 (3.6) |
| L-dopa equivalents (mg/day), mean (SD) | 481.5 (242.1) |
| Months since DBS-surgery, mean (SD) | 42.0 (20.1) |
| DBS parameter settings, mean (SD), Amplitude (V), pulse width (μs), Frequency (Hz) | Right: 3.4 (0.54) V, 66.7 (13.2)μs, 138.3 (40.2) Hz |
| Left: 3.4 (0.62) V, 66.7 (13.2)μs, 138.3 (40.2) Hz | |
| Location of contacts with negative polarity, in relation to the midpoint of the intercommissural line (IC), mean (SD) | Right: 11.3 (0.91) mm lateral, 3.5 (0.33) mm posterior, 2.4 (1.4) mm inferior. |
| Left: 11.3 (0.95) mm lateral, 3.9 (0.70) mm posterior, 2.8 (1.0) mm inferior. | |
| IC = 24.8 (0.59) mm | |
| UPDRS part III scores, without anti-PD medication | |
| - DBS turned OFF, median (q1-q3) | 42.5 (38.3-56.5) |
| - DBS turned ON, median (q1-q3) | 22.0 (17.5-25.3) |
Levodopa equivalents are calculated according to Østergaard et al., and Calne.
UPDRS part III: Unified Parkinson’s Disease Rating Scale, motor examination. Higher scores denote more severe motor symptoms. The maximum total score on the UPDRS part III is 108 points, and higher scores reflect more severe motor symptoms.
Without medication: Overnight withdrawal of all anti-Parkinsonian medication for 10–12 hours. All individuals were on L-dopa, and seven out of the nine participants were also on dopamine agonists (ranging from 20-50% of LED). When tested, all participants experienced off symptoms.
Of note, the assessments of severity of PD using UPDRS scores were done at the same occasion as the assessments of oculomotor functions.
Repeated-measures GLM ANOVA analysis of smooth pursuit parameters
| Gain | 10 | 0.97 (0.03) | 1.00 (0.01) | |||
| | 20 | 0.86 (0.04) | 0.97 (0.01) | | | |
| | 30 | 0.83 (0.05) | 0.94 (0.02) | | | |
| | 40 | 0.80 (0.04) | 0.90 (0.02) | | | |
| Velocity Accuracy | 10 | 31.7 (3.1) | 39.0 (2.5) | 0.188 (1.9) | ||
| | 20 | 37.3 (3.7) | 48.2 (3.1) | | | |
| | 30 | 35.8 (3.9) | 50.3 (3.5) | | | |
| 40 | 35.9 (3.3) | 46.1 (2.5) | ||||
Statistical evaluation of the smooth pursuit parameters (mean and SEM) using the repeated-measures GLM ANOVA method. Bold values indicate found significance (p < 0.05). The statistical F-values are presented within the parentheses after the p-values.
Figure 1A Gain values (mean and SEM) for four target velocities with DBS OFF and ON. A value below 1.00 represent that the average smooth pursuit velocity was below the target velocity. B: Smooth pursuit velocity accuracy values (mean and SEM) with DBS OFF and ON. A value of 100 % represents that the eye movement velocity were always within the boundaries. (# denotes P < 0.1; * denotes P < 0.05; ** denotes P < 0.01 and *** denotes P < 0.001).
Repeated-measures GLM ANOVA analysis of saccade parameters
| Velocity | 20 | 236 (16) | 269 (18) | 0.117 (2.8) | ||
| | 40 | 263 (20) | 288 (15) | | | |
| | 60 | 313 (34) | 332 (23) | | | |
| Amplitude Accuracy | 20 | 53.4 (4.2) | 65.8 (5.4) | 0.575 (0.4) | ||
| | 40 | 38.9 (4.4) | 49.0 (2.8) | | | |
| 60 | 34.6 (5.2) | 52.8 (5.3) | ||||
Statistical evaluation of the saccade parameters (mean and SEM) using the repeated-measures GLM ANOVA method. Bold values indicate found significance (p < 0.05), italic values indicate trends of significance (p < 0.1). F-values are presented within the parentheses after the p-values.
Figure 2A Saccade eye movement velocity (mean and SEM) for three saccade amplitudes with DBS OFF and ON. B: Saccade amplitude accuracy in percentage (mean and SEM) with DBS OFF and ON. A value of 100 represents perfect saccade amplitude accuracy whereas values below 100 represent short saccades (hypometric) (# denotes P < 0.1; * denotes P < 0.05; ** denotes P < 0.01 and *** denotes P < 0.001).
Correlation values between UPDRS motor scores and oculomotor parameters
| Gain | 10 | 0.305 (−0.256) | 0.131 (−0.369) |
| | 20 | 0.135 (−0.366) | |
| | 30 | 0.168 (−0.339) | 0.527 (−0.160) |
| | 40 | 0.243 (−0.310) | 0.670 (−0.108) |
| Velocity Accuracy | 10 | 0.150 (−0.354) | |
| | 20 | 0.767 (−0.075) | |
| | 30 | 0.627 (−0.123) | 0.532 (−0.158) |
| | 40 | 0.466 ( 0.196) | 0.521 (−0.162) |
| Latency | | 0.265 (−0.320) | 0.828 ( 0.059) |
| p-values | | | |
| | Target amplitudes (°) | DBS OFF | DBS ON |
| Velocity | 20 | 0.705 (−0.099) | |
| | 40 | 0.313 ( 0.252) | |
| | 60 | 0.539 ( 0.166) | 0.338 (−0.248) |
| Amplitude Accuracy | 20 | 0.518 (−0.168) | |
| | 40 | 0.503 ( 0.169) | |
| | 60 | 0.905 (−0.033) | 0.811 (−0.063) |
| Latency | 0.404 ( 0.217) | ||
Table 4A Correlation values between UPDRS motor scores and smooth pursuit parameters with DBS ON and DBS OFF. The correlation coefficient values are presented within the parentheses. Table 4B. Correlation values between UPDRS scores and saccade parameters with DBS ON and DBS OFF. Bold values indicate found significant correlation (p < 0.05), italic values indicate trends of correlation (p < 0.1). A negative correlation coefficient value suggests that PD subjects with higher UPDRS scores had poorer performance in the oculomotor parameter analyzed.